Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 31Myeloid 15Lymphoid 7Classical hematology 2Head & Neck 1Gynecologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Congenital Bone Marrow Failure Syndromes 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 11fludarabine phosphate 8fludarabine 8apixaban 8Mycophenolic Acid 6Melphalan 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rivaroxaban 4Filgrastim 4Biopsy 4thymoglobulin 3X-Rays 3Specimen Handling 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Hematopoietic Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Enoxaparin 3Bone Marrow Transplantation 3Azacitidine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2olaparib 2Tretinoin 2Stem Cell Transplantation 2Mesna 2Injections 2Heparin, Low-Molecular-Weight 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Decitabine × Classical hematology × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

NCT05796570 2026-03-19

MORE

Dana-Farber Cancer Institute

Phase 2 Recruiting
37 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Bone Marrow Failure Syndromes, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡